(Reuters) – Pfizer said on Tuesday its chief scientific officer Mikael Dolsten, a key figure behind the development of the company’s COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker.
The company said it would start identifying a successor for Dolsten, a process which is expected to last several months.
Dolsten joined Pfizer as part of the Wyeth acquisition in 2009, when he was named president of Worldwide Research and Development with the responsibility to lead all of Pfizer’s research as well as development of all its treatments through mid-stage studies.
(Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
Comments